

PERSONAL INFORMATION **Filip Josephson**

WORK EXPERIENCE

October 2008- Present **Clinical Assessor**
Medical Products Agency (Sweden)

EDUCATION AND TRAINING

1992- 1997 **M.D.**
karolinska Institute (Sweden)

2006- 2009 **Ph.D**
Karolinska Institute (Sweden)
Thesis entitled: "Studies on the Clinical Pharmacology of Antiretroviral Agents"

ADDITIONAL INFORMATION

Expertise Antivirals

Publications Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims. Marshall SF, Hemmings R, Josephson F, Karlsson MO, Posch M, Steimer JL. CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2:e27.

Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, Josephson F; For The Swedish Consensus Group. Scand J Infect Dis. 2012 Jul;44(7):502-521.

Novel clinical trial designs for the development of new antiretroviral agents. Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K. AIDS. 2012 May 15;26(8):899-907

Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Clin Infect Dis. 2012 Feb 1;54(3):408-13.

Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. Josephson F. J Intern Med. 2010 Dec;268(6):530-9

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010. Naver L, Albert J, Belfrage E, Flamholc L, Gisslen M, Gyllensten K, Josephson F, Karlstrom O, Lindgren S, Pettersson K, Svedhem V, Sonnerborg A, Westling K, Yilmaz A, Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis. 2011 Jul;43(6-7):411-23.

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naive HIV-1-infected patients. Eden A, Andersson LM, Andersson O, Flamholc L, Josephson F, Nilsson S, Ormaasen V, Svedhem V, Sall C, Sonnerborg A, Tunback P, Gisslen M. AIDS Res Hum Retroviruses. 2010 May;26(5):533-40.

Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Lagging M, Wejstal R, Uhnöo I, Gerden B, Fischler B, Friman S, Josephson F, Karlstrom O, Sangfelt P, Schwarz R, Weiland O; Swedish Consensus Group. Scand J Infect Dis. 2009;41(6-7):389-402.

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naive HIV-1 infected patients. Josephson F, Andersson MC, Flamholc L, Gisslen M, Hagberg L, Ormaasen V, Sonnerborg A, Vesterbacka J, Bottiger Y. Eur J Clin Pharmacol. 2010 Apr;66(4):349-57

Treatment of HIV infection: Swedish recommendations 2009. Josephson F, Albert J, Flamholz L, Gisslen M, Karlstrom O, Moberg L, Naver L, Svedhem V, Svennerholm B, Sonnerborg A; Swedish Medical Products Agency; Swedish Reference Group for Antiviral Therapy. *Scand J Infect Dis.* 2009;41(11-12):788-807.

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. Naver L, Bohlin AB, Albert J, Flamholz L, Gisslen M, Gyllensten K, Josephson F, Pehrson P, Sonnerborg A, Westling K, Lindgren S. *Scand J Infect Dis.* 2008;40(6-7):451-61.

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Josephson F, Bertilsson L, Bottiger Y, Flamholz L, Gisslen M, Ormaasen V, Sonnerborg A, Diczfalussy U. *Eur J Clin Pharmacol.* 2008 Aug;64(8):775-81.

Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Josephson F, Albert J, Flamholz L, Gisslen M, Karlstrom O, Lindgren SR, Naver L, Sandstrom E, Svedhem-Johansson V, Svennerholm B, Sonnerborg A. *Scand J Infect Dis.* 2007;39(6-7):486-507

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Josephson F, Allqvist A, Janabi M, Sayi J, Akiillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, Haefeli WE, Bertilsson L. *Clin Pharmacol Ther.* 2007 May;81(5):708-12.

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. Karlstrom O, Josephson F, Sonnerborg A. *J Acquir Immune Defic Syndr.* 2007 Apr 1;44(4):417-22.

Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. Gyllensten K, Josephson F, Lidman K, Saaf M. *AIDS.* 2006 Sep 11;20(14):1906-7.

Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, Ingelman-Sundberg M. *Pharmacogenet Genomics.* 2006 Mar;16(3):191-8.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)